Vanguard Portfolio Management’s Context Therapeutics CNTX Stock Holding History

Vanguard Portfolio Management’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$354K	Buy	+638,878	New	+$1.3M	﹤0.01%	3085

Other funds holding CNTX

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management's CNTX Position: Q2 2026 in Review

Vanguard Portfolio Management opened a new position in Context Therapeutics (CNTX) in Q2 2026: 638,878 shares worth $354K. The stake represents ﹤0.01% of the portfolio and ranks #3085 among its holdings.

43 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

Vanguard Portfolio Management held 638,878 shares of Context Therapeutics worth $354K as of Q2 2026.
Context Therapeutics was a new Vanguard Portfolio Management position in Q2 2026.
Context Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #3085 holding.
43 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.